Newswise — CHICAGO, IL — An investigational drug to treat Type 2 diabetes, empagliflozin, lowers blood pressure in patients with Type 2 diabetes and hypertension (high blood pressure), a new study finds. The results were presented Sunday in a late-breaking abstract at the joint meeting of the International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014 in Chicago.
This improvement in blood pressure reportedly was accompanied by a reduction in blood glucose (sugar) levels after 12 weeks of treatment with the drug, which is under development by Germany-based Boehringer Ingelheim Pharma.
“Tight blood pressure control in patients with hypertension and Type 2 diabetes is known to reduce the risk of death and complications related to diabetes,” said a study co-investigator, Afshin Salsali, MD, executive director of the Diabetes and Metabolism therapeutic area for Boehringer Ingelheim Pharma, which funded the study. “Our results suggest the potential to reduce the risk of cardiovascular events with long-term treatment.”
However, he emphasized that this hypothesis awaits confirmation in the long-term EMPA-REG OUTCOMETM trial (NCT01131676 on ClinicalTrials.gov), which is expected to complete in 2015.
The researchers tested two doses of empagliflozin, 10 milligrams (mg) and 25 mg, compared to a placebo, or “dummy” pill, in patients with Type 2 diabetes and high blood pressure, which ranged from 130 over 80 to 159 over 99 millimeters of mercury (mm Hg). Of the 824 patients, 276 received the lower dose of empagliflozin and another 276 received the higher dose; 272 patients received the placebo. All patients wore a blood pressure cuff that monitored their blood pressure at regular intervals for 24 hours before the start of the study and after 12 weeks of treatment. They also gave blood samples for checking their hemoglobin A1c, a measure of long-term blood sugar control.
Study data showed the differences between the average decreases with empagliflozin treatment and the average increases in results of patients treated with placebo. Empagliflozin at the 25-mg dose demonstrated the greatest 12-week reduction in both systolic blood pressure (the top number in a blood pressure reading) and diastolic blood pressure (bottom number). On average, blood pressure fell 4.2 mm Hg in comparison to placebo for systolic pressure and 1.7 mm Hg for diastolic in the group receiving 25 mg of empagliflozin. Patients who received the 10-mg dose had average decreases of 3.4 and 1.4 mm Hg compared to placebo in systolic and diastolic blood pressures, respectively.
From the start to the end of the study, the average hemoglobin A1c level dropped 0.62 percentage points with 10-mg empagliflozin and 0.65 percentage points with the 25-mg dose compared to placebo.
Salsali said empagliflozin improves blood sugar levels by reducing glucose re-absorption in the kidneys, leading to glucose elimination in the urine. He also said patients tolerated the drug well, with no increased rate of side effects in the empagliflozin groups compared to placebo. Most adverse events reported in all three groups were mild in intensity.
# # #
Founded in 1916, the Endocrine Society is the world’s oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, the Endocrine Society’s membership consists of over 17,000 scientists, physicians, educators, nurses and students in more than 100 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Washington, DC. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at https://twitter.com/#!/EndoMedia.